Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 6/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 6/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.43 |
| ▸ | MGLL | Q99685 | 3/20 | 0.42 |
| ▸ | SPR | P35270 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.40 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.39 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21893929 | 0.95 | KEAP1 (0.51) | KEAP1NFE2L2HSD11B1MGLLSPR | |
| SCHEMBL28621366 | 0.94 | KEAP1 (0.50) | KEAP1NFE2L2HSD11B1MGLLSPR | |
| SCHEMBL3678140 | 0.92 | NFE2L2 (0.58) | KEAP1NFE2L2MGLLSPRKDM4E | |
| SCHEMBL16488569 | 0.84 | HSD11B1 (0.47) | HSD11B1MGLLKDM4EPIM1 | |
| SCHEMBL31663216 | 0.81 | MGLL (0.43) | KEAP1NFE2L2HSD11B1MGLL | |
| SCHEMBL16488573 | 0.80 | LMNA (0.54) | HSD11B1KDM4EKMT2ASMN1; SMN2 | |
| Potassium Ion SCHEMBL21818514 | 0.79 | MGLL (0.42) | KEAP1NFE2L2HSD11B1MGLL | |
| SCHEMBL31662967 | 0.77 | MGLL (0.42) | KEAP1NFE2L2HSD11B1MGLLHTT | |
| SCHEMBL3491956 | 0.76 | KEAP1 (0.86) | KEAP1NFE2L2HSD11B1KMT2AL3MBTL1 | |
| SCHEMBL21893556 | 0.75 | KEAP1 (0.41) | KEAP1NFE2L2HSD11B1MGLLSPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9745288-B2 | Compounds and methods for treating cancer by inhibiting the urokinase receptor | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2017-08-29 | — | — | US | disclosed |
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2015-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051247-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER BY INHIBITING THE UROKINASE RECEPTOR | PLAUR, PLAU, PLG | KEAP1 2474/4885NFE2L2 2521/4885HSD11B1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.